Navacaprant
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Navacaprant
- Molecular weight
- 453.56
- Structure (SMILES)
- CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1
- btrx 140
- btrx 335140
- BTRX-140
- Btrx-335140
- BTRX-335140
- btrx335140
- BTRX335140
- cym 53093
- CYM-53093
- cym53093
- CYM53093
- navacaprant
- Navacaprant
- navacaprant [INN]
- NAVACAPRANT [USAN]
- navacaprant inn
- navacaprant usan
- nmra 140
- nmra 335140
- NMRA-140
- Nmra-335140
- NMRA-335140
- nmra335140
- NMRA335140
- CAS registry numbers
- 2244614-14-8
- ChEMBL ID
- CHEMBL4592045
- InChIKey
- CQOJHAJWCDJEAT-UHFFFAOYSA-N
- PubChem compound IDs
- 137434175
- FDA ingredient codes (UNII)
- XK5ILZ28KI
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- navacaprant
- Type
- Synthetic organic
- Drug name stem
- -caprant
- Action
- Antagonist
- Action type
- Antagonist
- Target
- μ receptor
- Gene symbol
- OPRM1
- Protein identifier
- P35372
- Median affinity
- 6.96
- Affinity units
- pIC50
- Action
- Antagonist
- Action type
- Antagonist
- Target
- δ receptor
- Gene symbol
- OPRD1
- Protein identifier
- P41143
- Median affinity
- 5.19
- Affinity units
- pIC50
- Action
- Antagonist
- Action type
- Antagonist
- Target
- κ receptor
- Gene symbol
- OPRK1
- Protein identifier
- P41145
- Median affinity
- 9.1
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- Kappa opioid receptor antagonist
- Action type
- Antagonist
- Target
- Kappa-type opioid receptor
- Protein identifier
- P41145
Open Targets mechanisms
- Mechanism
- Kappa opioid receptor antagonist
- Action type
- Antagonist
- Target
- Kappa-type opioid receptor
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Depression
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003863
- Condition identifier
- EFO_0007634
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002050
- NCT04221230
- NCT06029439
- NCT06058013
- NCT06058039
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 1
- Polar surface area
- 76.31
- Calculated partition coefficient (ALogP)
- 4.34
- Calculated partition coefficient (XLogP)
- 4.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 33
- Molecular formula
- C25H32FN5O2
- Monoisotopic mass
- 453.25400344
- Natural product
- No
- Recorded assays
- 36
- Active assays
- 10
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (6)
- Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
- Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
- Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
- Study to Assess the Safety and Effectiveness of NMRA-335140-501
- Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
- To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
In development for (2)
- Depressive disorder Phase 1
- Major depressive disorder Phase 3
Targets (1)
- OPRK1 Kappa opioid receptor antagonist